Five-Star Ranking

	A	B	C	D	E	F	G	H	I	J	K
1	Oncology
2		Company	Rating	Valuation	Price	Over/UnderValuation	Peak Value	Return	Time	Risk	Clinical Stage
3		BPMC	4.67	$105.44	$86.85	-17.63%	$725.34	588%	12 years	Moderate	Commercial
4		MRTX	4.07	$87.80	#N/A	#N/A	$806.60	819%	12 years	High	Phase 3
5		DCPH	3.77	$51.90	$14.67	-71.73%	$474.50	814%	10 years	High	Phase 3
6		FATE	4.16	$19.20	$4.79	-75.05%	$238.09	1140%	12 years	Very High	Phase 2
7		IOVA	3.47	$17.54	$11.31	-35.52%	$68.93	293%	8 years	High	Phase 3
8
9		Genetics
10		Company	Rating	Valuation	Price		Peak Value	Return	Time	Risk	Clinical Stage
11		RGNX	4.47	$46.74	$15.69	-66.43%	$636.85	1263%	10 years	Very High	Phase 1
12		KRYS	4.37	$67.34	$158.53	135.42%	$335.26	398%	10 years	High	Phase 2
13		CRSP	3.71	$35.57	$55.05	54.77%	$308.79	768%	10 years	Very High	Phase 1
14		SGMO	4.25	$17.43	$0.51	-97.07%	$109.57	529%	12 years	High	Phase 2
15		MRNA	3.72	$10.88	$101.41	832.08%	$127.21	1069%	12 years	Very High	Phase 1
16
17		Immunology
18		Company	Rating	Valuation	Price		Peak Value	Return	Time	Risk	Clinical Stage
19		ARGX	3.65	$101.42	$360.23	255.19%	$798.22	687%	10 years	High	Phase 3
20		RETA	4.15	$237.21	#N/A	#N/A	$1,269.69	435%	10 years	High	Phase 3
21		ALLK	4.05	$100.92	$1.07	-98.94%	$525.66	421%	10 years	Very High	Phase 3
22		APLS	3.5	$41.06	$47.53	15.76%	$190.73	365%	10 years	Very High	Phase 3
23		MNTA	3.4	$14.55	#N/A	#N/A	$111.49	666%	12 years	High	Phase 2
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100